A Phase 4 interventional study of TRYPTYR (Acoltremon ophthalmic solution 0.003%) in Sjogren Syndrome With Keratoconjunctivitis, sponsored by Center For Sight. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Center For Sight · Phase 4, Interventional, and Treatment
This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.
Center For Sight is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects must fulfill the following conditions to qualify for enrollment into the trial
Exclusion Criteria:
Subjects with any of the following conditions on the eligibility exam may NOT be enrolled into the trial.
The study eye is the eye with the lower pre-drop unanesthetized Schirmer score performed at the baseline visit.
Drug: TRYPTYR (Acoltremon ophthalmic solution 0.003%)
Drop to be instilled before and after endpoint measurement.
Change from pre-instillation to 3 minutes post-TRYPTYR instillation in study eye unanesthetized Schirmer's test at Visit 1 (baseline)
Unanesthetized Schirmer's test will be measured prior to instillation and then again 3 minutes after instillation of the TRYPTYR. The difference between the 2 measurements will be compared.
Time frame: 3 minutes
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center For Sight